iMolview vs BioViewer Usage & Stats

Explore the fascinating world of biological macromolecules: iMolview lets you browse and view in 3D protein and DNA structures from Protein Data Bank, drug molecules from DrugBank, and small molecules from Pubchem. Search for drug names like 'ibuprofen' or 'gefitinib' in DrugBank, or proteins like 'insulin' or 'thyroid receptor' in PDB. Information associated with each molecule in these databases is also at your fingertips. Sync and view your own structure files via iTunes. Molecular view can be customized with a rich set of molecular representations (wires, balls-and-sticks, space filling, ribbon diagrams, molecular surfaces) and various coloring schemes. Select residues, atoms or chains and color or change their representations individually. Select 'neighbors' of a ligand or any other selection to identify interacting atoms or residues. Set 'inertia' to the maximum and let your molecule spin in 3D indefinitely. Save the current scene (viewpoint + representation) as a slide which can be easily accessed later. Save the whole molecular document with multiple slides. Load and contour electron density map
  • Apple App Store
  • Paid
  • Education

Store Rank

- -

A .pdb protein visualizer for iOS, iPadOS and macOS. View the 3D representation of any molecular structure from a .pdb file, using our custom Metal-based rendering engine based to allow for a smooth experience even in the biggest proteins.  - Full drag and drop support for .pdb and .xyz files. - Photo Mode with publication-quality exports. - Support for multi-model PDBs. - Support for high refresh rate ProMotion displays.
  • Apple App Store
  • Free
  • Education

Store Rank

- -

iMolview vs. BioViewer ranking comparison

Compare iMolview ranking trend in the past 28 days vs. BioViewer

Rank

No Data Available

iMolview vs. BioViewer ranking by country comparison

Compare iMolview ranking trend in the past 28 days vs. BioViewer

No Data to Display

Compare to any site with our free trial

Get started
iMolview VS.
BioViewer

December 15, 2024